Ovarian carcinoma cells in effusions show increased S-phase fraction compared to corresponding primary tumors

Diagnostic Cytopathology

Volumn 36, Issue 9, 2008, Pages 637-644

  Kleinberg, Lilach ^a   Pradhan, Manohar ^a   Tropé, Claes G ^a,b   Nesland, Jahn M ^a,b   Davidson, Ben ^a,b   Risberg, Björn ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Chemoresistance; Disease progression; DNA ploidy; Serous effusions; Survival

Indexed keywords

BIOLOGICAL MARKER; CARBOPLATIN; CELL MARKER; EPIRUBICIN; GEMCITABINE; KI 67 ANTIGEN; MITOXANTRONE; PACLITAXEL; SURVIVIN; TAMOXIFEN CITRATE;

ADULT; AGED; ANEUPLOIDY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOMA CELL; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL FEATURE; DISEASE COURSE; EFFUSION; FEMALE; GENETIC ASSOCIATION; GENOMICS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PERITONEUM; PERITONEUM CANCER; PLEURA EFFUSION; PLOIDY; PRIMARY TUMOR; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANEUPLOIDY; CELL PROLIFERATION; DIPLOIDY; DNA, NEOPLASM; EXUDATES AND TRANSUDATES; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; S PHASE; SUBCELLULAR FRACTIONS; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 50849136823     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.20879     Document Type: Article

References (42)

1. Rajagopalan H, Lengauer C. Aneuploidy and cancer. Nature 2004;432:338-341.
2. Dey P. Aneuploidy and malignancy: An unsolved equation. J Clin Pathol 2004;57:1245-1249.
3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
4. Agarwal R, Kaye SB. Ovarian cancer: Strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003;3:502-516.
5. Davidson B. Malignant effusions: From diagnosis to biology. Diagn Cytopathol 2004;31:246-254.
6. Davidson B. Anatomic site-related expression of cancer-associated molecules in ovarian carcinoma. Curr Cancer Drug Targets 2007;7:109-120.
7. Erhardt K, Auer G, Björkholm E, et al. Prognostic significance of nuclear DNA content in serous ovarian tumors. Cancer Res 1984;44:2198-2202.
8. Friedlander ML, Hedley DW, Taylor IW, Russell P, Coates AS, Tattersall MH. Influence of cellular DNA content on survival in advanced ovarian cancer. Cancer Res 1984;44:397-400.
9. Volm M, Brüggemann A, Günther M, Kleine W, Pfleiderer A, Vogt-Schaden M. Prognostic relevance of ploidy, proliferation, and resistance-predictive tests in ovarian carcinoma. Cancer Res 1985;45:5180-5185.
10. Dobashi K, Stratton JA, Teplitz RL, Liao SY, Braly PS, Disaia PJ. Quantitative nuclear DNA analysis of human ovarian adenocarcinoma: Compared before and after chemotherapy and correlated with clinical response. Gynecol Oncol 1986;24:81-90.
11. Kallioniemi OP, Punnonen R, Mattila J, Lehtinen M, Koivula T. Prognostic significance of DNA index, multiploidy, and S-phase fraction in ovarian cancer. Cancer 1988;61:334-339.
12. Blumenfeld D, Braly PS, Ben-Ezra J, Klevecz RR. Tumor DNA content as a prognostic feature in advanced epithelial ovarian carcinoma. Gynecol Oncol 1987;27:389-402.
13. Rodenburg CJ, Ploem-Zaaijer JJ, Cornelisse CJ, et al. Use of DNA image cytometry in addition to flow cytometry for the study of patients with advanced ovarian cancer. Cancer Res 1987;47:3938-3941.
14. Kühn W, Kaufmann M, Feichter GE, Rummel HH, Schmid H, Heberling D. DNA flow cytometry, clinical and morphological parameters as prognostic factors for advanced malignant and borderline ovarian tumors. Gynecol Oncol 1989;33:360-367.
15. Klemi PJ, Joensuu H, Mäenpää J, Kiilholma P. Influence of cellular DNA content on survival in ovarian carcinoma. Obstet Gynecol 1989;74:200-204.
16. Sahni K, Tribukait B, Einhorn N. Flow cytometric measurement of ploidy and proliferation in effusions of ovarian carcinoma and their possible prognostic significance. Gynecol Oncol 1989;35:240-245.
17. Erba E, Ubezio P, Pepe S, et al. Flow cytometric analysis of DNA content in human ovarian cancers. Br J Cancer 1989;60:45-50.
18. Barnabei VM, Miller DS, Bauer KD, Murad TM, Rademaker AW, Lurain JR. Flow cytometric evaluation of epithelial ovarian cancer. Am J Obstet Gynecol 1990;162:1584-1590; discussion 1590-1592.
19. Brescia RJ, Barakat RA, Beller U, et al. The prognostic significance of nuclear DNA content in malignant epithelial tumors of the ovary. Cancer 1990;65:141-147.
20. Rotmensch J, Atcher RW, Schwartz JL, Grdina DJ. Analysis of ascites from patients with ovarian carcinoma hy cell flow cytometry. Gynecol Oncol 1992;44:10-12.
21. Berchuck A, Boente MP, Kerns BJ, et al. Ploidy analysis of epithelial ovarian cancers using image cytometry. Gynecol Oncol 1992; 44:61-5.
22. Kaern J, Wetteland J, Tropé CG, et al. Comparison between flow cytometry and image cytometry in ploidy distribution assessments in gynecologic cancer. Cytometry 1992;13:314-321.
23. Lage JM, Weinberg DS, Huettner PC, Mark SD. Flow cytometric analysis of nuclear DNA content in ovarian tumors. Association of ploidy with tumor type, histologic grade, and clinical stage. Cancer 1992;69:2668-2675.
24. Pfisterer J, Kommoss F, Sauerbrei W, et al. Cellular DNA content and survival in advanced ovarian carcinoma. Cancer 1994;74:2509-2515.
25. Kaern J, Tropé CG, Kristensen GB, Pettersen EO. Flow cytometric DNA ploidy and S-phase heterogeneity in advanced ovarian carcinoma. Cancer 1994;73:1870-1877.
26. Kaern J, Tropé CG, Kristensen GB, Tveit KM, Pettersen EO. Evaluation of deoxyribonucleic acid ploidy and S-phase fraction as prognostic parameters in advanced epithelial ovarian carcinoma: A prospective study. Am J Obstet Gynecol 1994;170:479-487.
27. Gajewski WH, Fuller AF Jr, Pastel-Ley C, Flotte TJ, Bell DA. Prognostic significance of DNA content in epithelial ovarian cancer. Gynecol Oncol 1994;53:5-12.
28. Venesmaa P, Paavonen J, Forss M, Ylikorkala O. Chemotherapy changes the DNA ploidy in ovarian cancer. Br J Obstet Gynaecol 1995;102:568-569.
29. Guidozzi F, Szumel RC, Ball JH, Johnston DA, Katz RL, Kidd L. Image analysis of cellular DNA content in peritoneal fluid of patients with ovarian tumors of low malignant potential and invasive epithelial ovarian cancer. Gynecol Oncol 1996;61:204-209.
30. Zanetta G, Keeney GL, Cha SS, et al. Flow-cytometric analysis of deoxyribonucleic acid content in advanced ovarian carcinoma: Its importance in long-term survival. Am J Obstet Gynecol 1996;175:1217-1225.
31. Kimball RE, Schlaerth JB, Kute TE, et al. Flow cytometric analysis of lymph node metastases in advanced ovarian cancer: Clinical and biologic significance. Am J Obstet Gynecol 1997;176:1319-1326; discussion 1326-1327.
32. Reles AE, Gee C, Schellschmidt I, et al. Prognostic significance of DNA content and S-phase fraction in epithelial ovarian carcinomas analyzed by image cytometry. Gynecol Oncol 1998;71:3-13.
33. Tewari KS, Kyshtoobayeva AS, Mehta RS, et al. Biomarker conservation in primary and metastatic epithelial ovarian cancer. Gynecol Oncol 2000;78:130-136.
34. Kimmig R, Wimberger P, Hillemanns P, Kapsner T, Caspari C, Hepp H. Multivariate analysis of the prognostic significance of DNA-ploidy and S-phase fraction in ovarian cancer determined by How cytometry following detection of cytokeratin-labeled tumor cells. Gynecol Oncol 2002;84:21-31.
35. Davidson B, Nielsen S, Christensen J, et al. The role of Desmin and N-cadherin in effusion cytology. A comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol 2001;25:1405-1412.
36. Kristensen GB, Kildal W, Abeler VM, et al. Large-scale genomic instability predicts long-term outcome for women with invasive stage I ovarian cancer. Ann Oncol 2003;14:1494-1500.
37. Kleinberg L, Flørenes VA, Silins I, et al. Nuclear expression of Survivin is associated with improved survival in metastatic ovarian carcinoma. Cancer 2007;109:228-238.
38. Davidson B, Skrede M, Silins I, Shih IeM, Trope' CG, Flørenes VA. Low molecular weight cyclin E forms differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma. Cancer 2007;110:1264-1271.
39. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998;396:580-584.
40. Mise K, Tashiro S, Yogita S, et al. Assessment of the biological malignancy of hepatocellular carcinoma: Relationship to clinicopathological factors and prognosis. Clin Cancer Res 1998;4:1475-1482.
41. Mariani A, Sebo TJ, Katzmann JA, et al. Pretreatment assessment of prognostic indicators in endometrial cancer. Am J Obstet Gynecol 2000;182:1535-1544.
42. Puntoni M, Zanardi S, Branchi D, et al. Prognostic effect of DNA aneuploidy from bladder washings in superficial bladder cancer. Cancer Epidemiol Biomarkers Prev 2007;16:979-983.